Investors deposited $819 million into health care and biotech funds this week — the largest weekly infusion of money into the sector since last July, according to a new report.

The timing of the big biotech inflow is also significant, coming in the same week that President Trump rolled out a series of proposals to lower prescription drug prices. Despite some sharp rhetoric, the snap judgment from Wall Street was that Trump’s plan would have limited impact on biotech and pharmaceuticals companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy